<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03936829</url>
  </required_header>
  <id_info>
    <org_study_id>C-PAALS&amp;T1D</org_study_id>
    <nct_id>NCT03936829</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide in the Treatment of Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes</brief_title>
  <official_title>Cyclophosphamide in the Treatment of Panniculitis Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the change of insulin resistance and glucose metabolism of patients with
      panniculitis associated acquired lipodystrophy syndrome and type 1 diabetes with the
      treatment of cyclophosphamide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with panniculitis associated acquired lipodystrophy syndrome and type 1 diabetes
      have difficulty in blood glucose management due to the presence of both severe insulin
      resistance and complete insulin deficiency. It is often necessary to use insulin doses
      several times that of other children of the same age with type 1 diabetes.

      Since autoimmune response is the main cause of panniculitis associated acquired lipodystrophy
      syndrome, immunosuppressive agents can suppress immune response, prevent and alleviate the
      progression of panniculitis and acquired lipodystrophy syndrome, and improve insulin
      resistance caused by subcutaneous fat deficiency.

      Cyclophosphamide is a classic immunosuppressive agent. This study hopes to improve insulin
      resistance of patients with panniculitis associated acquired lipodystrophy syndrome and type
      1 diabetes by cyclophosphamide treatment, thereby reducing insulin dosage and improving
      glucose metabolism.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average daily insulin dosage</measure>
    <time_frame>week 21</time_frame>
    <description>Average daily insulin dosage of continuous three days (the average of the 1st, 2nd and 3rd days' insulin requirements after the last cyclophosphamide treatment, the blood glucose meets the ISPAD guideline as premeal 4.0-7.0 mmol/L, postmeal 5.0-10.0 mmol/L, prebed 4.4-7.8 mmol/L)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average daily insulin dosage</measure>
    <time_frame>week 1</time_frame>
    <description>Average daily insulin dosage of continuous three days (the average of the 1st, 2nd and 3rd days' insulin requirements after the first cyclophosphamidethe, blood glucose meets the ISPAD guideline as premeal 4.0-7.0 mmol/L, postmeal 5.0-10.0 mmol/L, prebed 4.4-7.8 mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daily insulin dosage</measure>
    <time_frame>week 5</time_frame>
    <description>Average daily insulin dosage of continuous three days (the average of the 1st, 2nd and 3rd days' insulin requirements after the 2nd cyclophosphamide, the blood glucose meets the ISPAD guideline as premeal 4.0-7.0 mmol/L, postmeal 5.0-10.0 mmol/L, prebed 4.4-7.8 mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daily insulin dosage</measure>
    <time_frame>week 9</time_frame>
    <description>Average daily insulin dosage of continuous three days (the average of the 1st, 2nd and 3rd days' insulin requirements after the 3rd cyclophosphamide, the blood glucose meets the ISPAD guideline as premeal 4.0-7.0 mmol/L, postmeal 5.0-10.0 mmol/L, prebed 4.4-7.8 mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daily insulin dosage</measure>
    <time_frame>week 13</time_frame>
    <description>Average daily insulin dosage of continuous three days (the average of the 1st, 2nd and 3rd days' insulin requirements after the 4th cyclophosphamide, the blood glucose meets the ISPAD guideline as premeal 4.0-7.0 mmol/L, postmeal 5.0-10.0 mmol/L, prebed 4.4-7.8 mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daily insulin dosage</measure>
    <time_frame>week 17</time_frame>
    <description>Average daily insulin dosage of continuous three days (the average of the 1st, 2nd and 3rd days' insulin requirements after the 5th cyclophosphamide, the blood glucose meets the ISPAD guideline as premeal 4.0-7.0 mmol/L, postmeal 5.0-10.0 mmol/L, prebed 4.4-7.8 mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daily insulin dosage</measure>
    <time_frame>from the completion of treatment to 3 months</time_frame>
    <description>Average daily insulin dosage of continuous three days (the average of 3 days' insulin requirements 3 months after the last cyclophosphamide treatment, the blood glucose meets the ISPAD guideline as premeal 4.0-7.0 mmol/L, postmeal 5.0-10.0 mmol/L, prebed 4.4-7.8 mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daily insulin dosage</measure>
    <time_frame>from the completion of treatment to 6 months</time_frame>
    <description>Average daily insulin dosage of continuous three days (the average of 3 days' insulin requirements 6 months after the last cyclophosphamide treatment, the blood glucose meets the ISPAD guideline as premeal 4.0-7.0 mmol/L, postmeal 5.0-10.0 mmol/L, prebed 4.4-7.8 mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daily insulin dosage</measure>
    <time_frame>from the completion of treatment to 9 months</time_frame>
    <description>Average daily insulin dosage of continuous three days (the average of 3 days' insulin requirements 9 months after the last cyclophosphamide treatment, the blood glucose meets the ISPAD guideline as premeal 4.0-7.0 mmol/L, postmeal 5.0-10.0 mmol/L, prebed 4.4-7.8 mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daily insulin dosage</measure>
    <time_frame>from the completion of treatment to 12 months</time_frame>
    <description>Average daily insulin dosage of continuous three days (the average of 3 days' insulin requirements 12 months after the last cyclophosphamide treatment, the blood glucose meets the ISPAD guideline as premeal 4.0-7.0 mmol/L, postmeal 5.0-10.0 mmol/L, prebed 4.4-7.8 mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c level</measure>
    <time_frame>week 1</time_frame>
    <description>HbA1c level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c level</measure>
    <time_frame>week 5</time_frame>
    <description>HbA1c level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c level</measure>
    <time_frame>week 9</time_frame>
    <description>HbA1c level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c level</measure>
    <time_frame>week 13</time_frame>
    <description>HbA1c level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c level</measure>
    <time_frame>week 17</time_frame>
    <description>HbA1c level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c level</measure>
    <time_frame>week 21</time_frame>
    <description>HbA1c level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c level</measure>
    <time_frame>from the completion of treatment to 3 months</time_frame>
    <description>HbA1c level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c level</measure>
    <time_frame>from the completion of treatment to 6 months</time_frame>
    <description>HbA1c level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c level</measure>
    <time_frame>from the completion of treatment to 9 months</time_frame>
    <description>HbA1c level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c level</measure>
    <time_frame>from the completion of treatment to 12 months</time_frame>
    <description>HbA1c level</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Lipodystrophy Acquired</condition>
  <condition>Type1diabetes</condition>
  <arm_group>
    <arm_group_label>Interventional</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug:Cyclophosphamide Dosage form: intravenous infusion Dosage: 500 mg/m2 of BSA Frequency: every 4 weeks Duration: 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Admitted to the hospital every 4 weeks. Cyclophosphamide was intravenously instilled (500mg mg/m2 of BSA) after contraindications are excluded. ECG monitoring will be taken during the medication. A total of 6 treatments will be performed.</description>
    <arm_group_label>Interventional</arm_group_label>
    <other_name>CYC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Meet the diagnostic criteria of type 1 diabetes mellitus: clinical manifestations of
             typical diabetes mellitus include polyphagia, polyuria, weight loss, or diabetic
             ketoacidosis, confirmed by blood sugar level, islet function and autoimmune antibody.

          2. Meet the diagnostic criteria for panniculitis: fat biopsy suggests inflammatory
             infiltration.

          3. Meet the diagnostic criteria for acquired lipodystrophy syndrome: childhood onset,
             clinically no nutritional deficiency or catabolism, systemic or partial subcutaneous
             fat reduction, genetic testing to exclude congenital lipodystrophy syndrome; low
             leptin level and autoantibodies can aid in diagnosis.

        Exclusion Criteria:

          1. Mature and effective treatment methods are available.

          2. HIV, HBV and HCV were positive.

          3. A the active period of infection.

          4. At the active stage of malignant tumors.

          5. Combination of other fatal diseases.

          6. Existence of mental and psychological diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feihong Luo</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital of Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feihong Luo</last_name>
    <phone>+862164931226</phone>
    <phone_ext>+862164931226</phone_ext>
    <email>luofh@fudan.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhenran H Xu</last_name>
    <phone>+862164931226</phone>
    <phone_ext>+862164931226</phone_ext>
    <email>xu_zhenran@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feihong Luo</last_name>
      <phone>+862164931226</phone>
      <phone_ext>+862164931226</phone_ext>
      <email>luofh@fudan.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Zhenran Xu</last_name>
      <phone>+862164931226</phone>
      <phone_ext>+862164931226</phone_ext>
      <email>xu_zhenran@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Lebastchi J, Ajluni N, Neidert A, Oral EA. A Report of Three Cases With Acquired Generalized Lipodystrophy With Distinct Autoimmune Conditions Treated With Metreleptin. J Clin Endocrinol Metab. 2015 Nov;100(11):3967-70. doi: 10.1210/jc.2015-2589. Epub 2015 Sep 21.</citation>
    <PMID>26390101</PMID>
  </reference>
  <reference>
    <citation>Kumar R, Pilania RK, Bhatia A, Dayal D. Acquired generalised lipodystrophy and type 1 diabetes mellitus in a child: a rare and implacable association. BMJ Case Rep. 2018 Aug 3;2018. pii: bcr-2018-225553. doi: 10.1136/bcr-2018-225553.</citation>
    <PMID>30076164</PMID>
  </reference>
  <reference>
    <citation>Gupta N, Asi N, Farah W, Almasri J, Barrionuevo P, Alsawas M, Wang Z, Haymond MW, Brown RJ, Murad MH. Clinical Features and Management of Non-HIV-Related Lipodystrophy in Children: A Systematic Review. J Clin Endocrinol Metab. 2017 Feb 1;102(2):363-374. doi: 10.1210/jc.2016-2271. Review.</citation>
    <PMID>27967300</PMID>
  </reference>
  <reference>
    <citation>Carroll M, Mellick N, Wagner G. Dermatomyositis panniculitis: a case report. Australas J Dermatol. 2015 Aug;56(3):224-6. doi: 10.1111/ajd.12172. Epub 2014 Apr 1.</citation>
    <PMID>24689899</PMID>
  </reference>
  <reference>
    <citation>Li S, Yang H, Guo P, Ao X, Wan J, Li Q, Tan L. Efficacy and safety of immunosuppressive medications for steroid-resistant nephrotic syndrome in children: a systematic review and network meta-analysis. Oncotarget. 2017 Aug 21;8(42):73050-73062. doi: 10.18632/oncotarget.20377. eCollection 2017 Sep 22.</citation>
    <PMID>29069848</PMID>
  </reference>
  <reference>
    <citation>Brown RJ, Meehan CA, Cochran E, Rother KI, Kleiner DE, Walter M, Gorden P. Effects of Metreleptin in Pediatric Patients With Lipodystrophy. J Clin Endocrinol Metab. 2017 May 1;102(5):1511-1519. doi: 10.1210/jc.2016-3628.</citation>
    <PMID>28324110</PMID>
  </reference>
  <reference>
    <citation>Chong AY, Lupsa BC, Cochran EK, Gorden P. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia. 2010 Jan;53(1):27-35. doi: 10.1007/s00125-009-1502-9. Epub 2009 Sep 2.</citation>
    <PMID>19727665</PMID>
  </reference>
  <reference>
    <citation>Joffe BI, Panz VR, Raal FJ. From lipodystrophy syndromes to diabetes mellitus. Lancet. 2001 May 5;357(9266):1379-81. Review.</citation>
    <PMID>11356429</PMID>
  </reference>
  <reference>
    <citation>Hussain I, Patni N, Garg A. Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease. Pathology. 2019 Feb;51(2):202-212. doi: 10.1016/j.pathol.2018.11.004. Epub 2018 Dec 27. Review.</citation>
    <PMID>30595509</PMID>
  </reference>
  <reference>
    <citation>Weingartner JS, Zedek DC, Burkhart CN, Morrell DS. Lupus erythematosus panniculitis in children: report of three cases and review of previously reported cases. Pediatr Dermatol. 2012 Mar-Apr;29(2):169-76. doi: 10.1111/j.1525-1470.2011.01544.x. Epub 2011 Nov 8. Review.</citation>
    <PMID>22066977</PMID>
  </reference>
  <reference>
    <citation>Diker-Cohen T, Cochran E, Gorden P, Brown RJ. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. J Clin Endocrinol Metab. 2015 May;100(5):1802-10. doi: 10.1210/jc.2014-4491. Epub 2015 Mar 3.</citation>
    <PMID>25734254</PMID>
  </reference>
  <reference>
    <citation>Ale'ed A, Alsonbul A, Al-Mayouf SM. Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus. Rheumatol Int. 2014 Apr;34(4):529-33. doi: 10.1007/s00296-013-2896-8. Epub 2013 Nov 12.</citation>
    <PMID>24218286</PMID>
  </reference>
  <reference>
    <citation>Park JY, Chong AY, Cochran EK, Kleiner DE, Haller MJ, Schatz DA, Gorden P. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy. J Clin Endocrinol Metab. 2008 Jan;93(1):26-31. Epub 2007 Oct 16.</citation>
    <PMID>17940115</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 25, 2019</study_first_submitted>
  <study_first_submitted_qc>May 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2019</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>panniculitis associated acquired generalised lipodystrophy</keyword>
  <keyword>cyclophosphamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipodystrophy</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT03936829/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT03936829/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT03936829/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

